| Literature DB >> 31546768 |
Mercedes Sotos-Prieto1,2,3,4, Costas Christophi5,6, Alicen Black7, Jeremy D Furtado8, Yiqing Song9, Prokopios Magiatis10, Aikaterini Papakonstantinou11, Eleni Melliou12, Steven Moffatt13, Stefanos N Kales14.
Abstract
Collecting dietary intake data is associated with challenges due to the subjective nature of self-administered instruments. Biomarkers may objectively estimate the consumption of specific dietary items or help assess compliance in dietary intervention studies. Our aim was to use a panel of plasma and urine biomarkers to assess the validity of self-reported dietary intake using a modified Mediterranean Diet Scale (mMDS) among firefighters participating in Feeding America's Bravest (FAB), an MD cluster-randomized controlled trial. In our nested biomarker pilot study, participants were randomly selected from both the MD intervention group (n = 24) and the control group (n = 24) after 12-months of dietary intervention. At baseline data collection for the pilot study (t = 12-months of FAB), participants in the control group crossed-over to receive the MD intervention (active intervention) for 6-months. Participants in the intervention group continued in a self-sustained continuation phase (SSP) of the intervention. Food frequency questionnaires (FFQ), 13-item-mMDS questionnaires, 40 plasma fatty acids, inflammatory biomarkers and urinary hydroxytyrosol and tyrosol were analyzed at both time points. Spearman's correlation, t-tests and linear regression coefficients were calculated using SAS software. Overall, the mMDS derived from the FFQ was highly correlated with the specific 13-domain-mMDS (r = 0.74). The concordance between the two questionnaires for low and high adherence to MD was high for all the participants in the parent trial (κ = 0.76). After 6 months of intervention in the pilot study, plasma saturated fatty acid decreased in both groups (active intervention: -1.3 ± 1.7; p = 0.002; SSP: -1.12 ± 1.90; p = 0.014) and oleic acid improved in the SSP (p = 0.013). Intake of olive oil was positively associated with plasma omega-3 (p = 0.004) and negatively with TNF-α (p < 0.001) at baseline. Choosing olive oil as a type of fat was also associated with higher levels of plasma omega-3 (p = 0.019) at baseline and lower TNF-α (p = 0.023) at follow up. Intake of red and processed meats were associated with lower serum omega-3 (p = 0.04) and fish consumption was associated with lower IL-6 at baseline (p = 0.022). The overall mMDS was associated with an increase in plasma omega-3 (p = 0.021). Good correlation was found between nutrient intake from the FFQ and the corresponding plasma biomarkers (omega-3, EPA and DHA). In this MD randomized controlled trial, some key plasma biomarkers were significantly associated with key MD diet components and the overall mMDS supporting the validity of the mMDS questionnaire as well as compliance with the intervention.Entities:
Keywords: biomarkers; compliance; mediterranean diet; validation
Mesh:
Substances:
Year: 2019 PMID: 31546768 PMCID: PMC6769698 DOI: 10.3390/nu11092250
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Study design and timeline of “Feeding America’s Bravest” Mediterranean diet nutrition intervention study. January 2018 marks the beginning of the current pilot biomarker sub-study.
Baseline demographic and lifestyle characteristics of the parent trial and pilot trial.
| Overall Feeding America’s Bravest | Pilot –Biomarkers Study (Baseline) | |||||||
|---|---|---|---|---|---|---|---|---|
| All ( | Control ( | Intervention ( | All ( | Control ( | Intervention ( | |||
| Age (years) | 48.36 ± 8.29 | 49.02 ± 7.86 | 47.67 ± 8.68 | 0.096 | 47.52 ± 7.63 | 47.58 ± 8.63 | 47.46 ± 6.67 | 0.955 |
| Gender | 0.140 | 0.520 | ||||||
| Males | 250 (94.7%) | 122 (96.8%) | 128 (92.8%) | 38 (92.7%) | 20 (95.2%) | 18 (90.0%) | ||
| Females | 14 (5.3%) | 4 (3.2%) | 10 (7.2%) | 3 (7.3%) | 1 (4.8%) | 2 (10.0%) | ||
| Race | 0.003 | 0.563 | ||||||
| Caucasian | 217 (82.8%) | 112 (89.6%) | 105 (76.6%) | 31 (79.5%) | 16 (80.0%) | 15 (78.9%) | ||
| African American | 39 (14.9%) | 9 (7.2%) | 30 (21.9%) | 7 (17.9%) | 3 (15.0%) | 4 (21.1%) | ||
| Other | 6 (2.3%) | 4 (3.2%) | 2 (1.5%) | 1 (2.6%) | 1 (5.0%) | 0 (0.0%) | ||
| BMI (kg/m2) | 29.97 ± 4.48 | 30.13 ± 4.47 | 29.80 ± 4.50 | 0.447 | 29.68 ± 3.50 | 31.13 ± 3.07 | 28.24 ± 3.35 | 0.003 |
| BMI group | 0.785 | 0.094 | ||||||
| 18.5–25 | 49 (11.9%) | 24 (11.4%) | 25 (12.4%) | 5 (10.4%) | 1 (4.2%) | 4 (16.7%) | ||
| 25–30 | 185 (44.8%) | 98 (46.4%) | 87 (43.1%) | 20 (41.7%) | 8 (33.3%) | 12 (50.0%) | ||
| 30+ | 179 (43.3%) | 89 (42.2%) | 90 (44.6%) | 23 (47.9%) | 15 (62.5%) | 8 (33.3%) | ||
| Smoking | 0.433 | 0.520 | ||||||
| Yes | 11 (4.2%) | 4 (3.1%) | 7 (5.1%) | 3 (7.3%) | 1 (4.8%) | 2 (10.0%) | ||
| No | 254 (95.8%) | 123 (96.9%) | 131 (94.9%) | 38 (92.7%) | 20 (95.2%) | 18 (90.0%) | ||
| Overall mMDS (0–51 points) | 24.08 ± 5.73 | 24.38 ± 5.61 | 23.78 ± 5.85 | 0.284 | 25.02 ± 5.79 | 26.00 ± 5.00 | 24.04 ± 6.44 | 0.245 |
| FFQ-derived mMDS | 22.05 ± 6.89 | 21.95 ± 6.97 | 22.16 ± 6.82 | 0.753 | 26.42 ± 4.79 | 27.88 ± 4.78 | 24.96 ± 4.44 | 0.034 |
| CRP (ngmL) | N/A | N/A | N/A | 1733 ± 2041 | 1640 ± 1936 | 1827 ± 2179 | 0.754 | |
| TNF-α (pgmL) | N/A | N/A | N/A | 1.09 ± 0.35 | 1.14 ± 0.39 | 1.04 ± 0.31 | 0.308 | |
| IL-6 (pgmL) | N/A | N/A | N/A | 1.92 ± 2.15 | 1.69 ± 1.14 | 2.15 ± 2.84 | 0.489 | |
| MUFA (%) | N/A | N/A | N/A | 22.33 ± 3.16 | 22.98 ± 3.16 | 21.69 ± 3.08 | 0.157 | |
| PUFA (%) | N/A | N/A | N/A | 47.14 ± 4.15 | 46.89 ± 4.00 | 47.39 ± 4.37 | 0.682 | |
Agreement between the modified Mediterranean Diet Score (mMDS) and the mMDS derived from the food frequency questionnaire (FFQ) in the overall population at baseline and in the lot study at both baseline and 6 months follow-up.
| mMDS FFQ Derived | |||||||
|---|---|---|---|---|---|---|---|
| mMDS Questionnaire | Agree (Low-Low) | Agree (High-High) | Disagree (Low-High) | Disagree (High-Low) | r | k (95%CI) | ICC |
| Overall (parent trial baseline) | 183 (43%) | 192 (45%) | 27 (6%) | 24 (6%) | 0.76 ( | 0.76 (95% CI: 0.70, 0.82) | 0.76 (95% CI: 0.72, 0.80) |
| Pilot study baseline | 15 (31%) | 15 (31%) | 8 (17%) | 10 (21%) | 0.25 ( | 0.25 (95% CI: −0.02, 0.52) | 0.11 (95% CI: −0.21, 0.41) |
| Pilot study 6 m follow-up | 15 (37%) | 19 (46%) | 4 (10%) | 3 (7%) | 0.66 ( | 0.66 (95% CI: 0.42, 0.89) | 0.65 (95% CI: 0.44, 0.79) |
Figure 2Bland-Altman Plots indicating the mean difference between indices obtained from the FFQ and the corresponding mMDS questionnaires vs the mean of the two indices for the overall population [baseline] and the pilot study [12 months follow up (baseline for the pilot study); 18 months follow up (6 months follow-up for the pilot study)]. The red lines refer to the mean difference as well as the lower and upper bounds (2 standard deviations above and below the mean). The dots correspond to the different participants.
Levels and changes in plasma, urine biomarkers and mMDS at baseline and 6 months follow up in the pilot trial of “Feeding Americas Bravest.”
| Variable | Control Active Intervention | Intervention Self Sustained-Continuation Phase | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | 6-Months Follow-Up | Changes | Baseline | 6-Months Follow-Up | Changes | ||||||||||||||||
| N | Mean | SD | N | Mean | SD | N | Mean | SD | N | Mean | SD | N | Mean | SD | N | Mean | SD | ||||
| TNF-α (pgmL) | 24 | 1.14 | 0.39 | 20 | 1.22 | 0.44 | 20 | 0.053 | 0.228 | 0.315 | 24 | 1.04 | 0.31 | 21 | 1.21 | 0.35 | 21 | 0.181 | 0.289 | 0.009 | 0.123 |
| IL6 (pgmL) | 22 | 1.69 | 1.14 | 20 | 1.88 | 2.48 | 18 | 0.209 | 2.668 | 0.744 | 22 | 2.15 | 2.84 | 21 | 2.51 | 4.29 | 20 | 0.363 | 5.279 | 0.762 | 0.909 |
| CRP (ngmL) | 24 | 1640 | 1936 | 20 | 1084 | 1232 | 20 | −619 | 1656 | 0.111 | 24 | 1827 | 2179 | 21 | 1584 | 1783 | 21 | −19 | 2185 | 0.969 | 0.330 |
| Tyrosol (ppm) | 18 | 0.019 | 0.026 | 14 | 0.024 | 0.015 | 9 | 0.013 | 0.019 | 0.072 | 19 | 0.020 | 0.033 | 16 | 0.016 | 0.006 | 13 | 0.002 | 0.014 | 0.569 | 0.149 |
| Hydroxytyrosol (ppm) | 23 | 0.105 | 0.094 | 17 | 0.090 | 0.082 | 16 | −0.018 | 0.082 | 0.400 | 24 | 0.137 | 0.105 | 17 | 0.095 | 0.073 | 17 | −0.033 | 0.120 | 0.275 | 0.681 |
| SFA (%) | 24 | 29.01 | 1.42 | 20 | 27.64 | 1.46 | 20 | −1.347 | 1.679 |
| 24 | 29.74 | 1.66 | 21 | 28.49 | 1.80 | 21 | −1.118 | 1.897 |
| 0.686 |
| Oleic Acid (%) | 24 | 19.45 | 3.06 | 20 | 19.64 | 2.08 | 20 | −0.042 | 2.897 | 0.949 | 24 | 18.02 | 2.83 | 21 | 19.06 | 2.81 | 21 | 1.052 | 1.766 |
| 0.157 |
| Alpha-linolenic Acid (%) | 24 | 31.36 | 3.37 | 20 | 32.69 | 3.33 | 20 | 1.461 | 3.682 | 0.092 | 24 | 31.60 | 3.83 | 21 | 31.10 | 3.88 | 21 | −0.756 | 3.917 | 0.387 | 0.070 |
| Linoleic Acid (%) | 24 | 0.63 | 0.23 | 20 | 0.68 | 0.26 | 20 | 0.023 | 0.219 | 0.645 | 24 | 0.64 | 0.16 | 21 | 0.67 | 0.17 | 21 | 0.004 | 0.210 | 0.938 | 0.775 |
| Omega 3 fatty acid (%) | 24 | 3.35 | 0.91 | 20 | 3.54 | 0.96 | 20 | 0.056 | 0.553 | 0.654 | 24 | 3.91 | 1.25 | 21 | 3.82 | 1.08 | 21 | −0.082 | 0.978 | 0.704 | 0.579 |
| mMDS (0–51 points) | 24 | 26.00 | 5.00 | 22 | 26.93 | 4.74 | 22 | 1.063 | 4.613 | 0.292 | 24 | 24.04 | 6.44 | 22 | 25.05 | 5.47 | 22 | 1.231 | 5.140 | 0.274 | 0.909 |
TNF-α: Tumor necrosis factor; IL-6: Interleukin 6; CRP: C-Reactive Protein; SFA: Saturated Fatty Acids; mMDS: modified Mediterranean Diet Score; FFQ: Food frequency questionnaire. # paired t-test testing whether the mean difference is different than 0 ^ t-test testing whether the mean difference in Group 0 is different than the mean difference in Group 1.
Modified Mediterranean Diet food groups (from the mMDS questionnaire) association with plasma and urine biomarkers at baseline and 6 months follow-up in the pilot study of the Feeding Americas Bravest.
| Baseline ( | 6 Months Follow-Up ( | |||||||
|---|---|---|---|---|---|---|---|---|
| β | SE |
| R2 | β | SE |
| R2 | |
| Olive oil with | ||||||||
| CRP (ngmL) | −582.06 | 402.82 | 0.157 | 0.10 | 676.12 | 365.72 | 0.077 | 0.13 |
| TNF-α (pgmL) | −0.257 | 0.066 | <0.001 | 0.31 | −0.012 | 0.114 | 0.919 | 0.002 |
| IL-6 (pgmL) | −0.156 | 0.543 | 0.776 | 0.03 | 0.653 | 0.611 | 0.296 | 0.069 |
| MUFA (%) | −0.518 | 0.623 | 0.412 | 0.08 | 0.123 | 0.648 | 0.852 | 0.004 |
| Oleic acid (%) | −0.437 | 0.586 | 0.460 | 0.08 | 0.124 | 0.545 | 0.822 | 0.009 |
| Omega 3 (%) | 0.663 | 0.218 | 0.004 | 0.24 | 0.491 | 0.272 | 0.083 | 0.120 |
| Omega 6 (%) | −0.162 | 0.850 | 0.850 | 0.00 | −0.396 | 0.918 | 0.670 | 0.026 |
| Omega 9 (%) | −0.556 | 0.635 | 0.387 | 0.06 | 0.090 | 0.650 | 0.891 | 0.002 |
| Hydroxytyrosol (ppm) | 0.038 | 0.019 | 0.058 | 0.11 | 0.005 | 0.020 | 0.790 | 0.014 |
| Tyrosol (ppm) | 0.003 | 0.007 | 0.721 | 0.01 | −0.007 | 0.004 | 0.081 | 0.221 |
| Olive oil as oil most frequently used with | ||||||||
| CRP (ngmL) | −504.39 | 660.75 | 0.450 | 0.06 | 131.02 | 582.42 | 0.824 | 0.003 |
| TNF-α (pgmL) | −0.13320 | 0.12563 | 0.296 | 0.048 | −0.37219 | 0.15281 | 0.023 | 0.199 |
| IL-6 (pgmL) | 0.61535 | 0.83815 | 0.468 | 0.039 | 0.70396 | 0.92189 | 0.453 | 0.048 |
| MUFA (%) | 0.131 | 1.011 | 0.898 | 0.06 | 0.696 | 0.957 | 0.475 | 0.024 |
| Oleic acid (%) | 0.036 | 0.948 | 0.970 | 0.06 | 0.463 | 0.808 | 0.572 | 0.020 |
| Omega 3 (%) | 0.89628 | 0.36287 | 0.019 | 0.183 | 0.20528 | 0.42999 | 0.637 | 0.010 |
| Omega 6 (%) | −1.33274 | 1.34777 | 0.330 | 0.027 | −0.42694 | 1.37174 | 0.758 | 0.022 |
| Omega 9 (%) | 0.10684 | 1.03085 | 0.918 | 0.047 | 0.56453 | 0.96316 | 0.563 | 0.016 |
| Hydroxytyrosol (ppm) | 0.02982 | 0.03239 | 0.364 | 0.031 | −0.05012 | 0.02876 | 0.097 | 0.141 |
| Tyrosol (ppm) | −0.01744 | 0.01281 | 0.185 | 0.067 | −0.00006872 | 0.00715 | 0.992 | 0.063 |
| Fast Food with | ||||||||
| TNF-α (pgmL) | 0.02919 | 0.05935 | 0.626 | 0.024 | 0.11427 | 0.08914 | 0.212 | 0.066 |
| IL-6 (pgmL) | −0.16980 | 0.38495 | 0.662 | 0.028 | −0.03013 | 0.50372 | 0.953 | 0.025 |
| SFA (%) | 0.25249 | 0.23367 | 0.287 | 0.124 | −0.40098 | 0.38530 | 0.308 | 0.076 |
| Trans fat (%) | 0.02804 | 0.02014 | 0.173 | 0.069 | −0.07291 | 0.11761 | 0.541 | 0.107 |
| Red and processed meats with | ||||||||
| TNF-α (pgmL) | −0.01099 | 0.03673 | 0.766 | 0.020 | 0.06130 | 0.03965 | 0.135 | 0.092 |
| IL-6 (pgmL) | 0.10635 | 0.23932 | 0.660 | 0.028 | −0.05615 | 0.22705 | 0.807 | 0.027 |
| SFA (%) | 0.16769 | 0.14391 | 0.252 | 0.129 | −0.04400 | 0.17753 | 0.806 | 0.036 |
| Omega 3 (%) | −0.22092 | 0.10696 | 0.046 | 0.145 | −0.17799 | 0.09880 | 0.084 | 0.119 |
| Omega 6 (%) | 0.17853 | 0.39255 | 0.652 | 0.006 | 0.15885 | 0.33333 | 0.638 | 0.027 |
| Nuts with | ||||||||
| TNF-α (pgmL) | 0.00314 | 0.05098 | 0.951 | 0.018 | 0.05098 | 0.05688 | 0.379 | 0.034 |
| IL-6 (pgmL) | −0.41093 | 0.31558 | 0.202 | 0.072 | −0.13178 | 0.31502 | 0.679 | 0.031 |
| Omega 3 (%) | 0.16628 | 0.15453 | 0.289 | 0.071 | 0.03149 | 0.14626 | 0.831 | 0.002 |
| Omega 6 (%) | −0.15244 | 0.54522 | 0.781 | 0.002 | 0.76669 | 0.43868 | 0.093 | 0.129 |
| Linoleic acid (%) | 0.02443 | 0.49517 | 0.961 | 0.004 | 0.97259 | 0.49793 | 0.063 | 0.172 |
| n-6 Linolenic acid (%) | −0.03366 | 0.02793 | 0.236 | 0.041 | −0.01286 | 0.03494 | 0.716 | 0.006 |
| Fish with | ||||||||
| TNF-α (pgmL) | 0.02446 | 0.04830 | 0.616 | 0.025 | −0.07476 | 0.07311 | 0.317 | 0.043 |
| IL-6 (pgmL) | −0.70823 | 0.29396 | 0.022 | 0.172 | −0.00409 | 0.40835 | 0.992 | 0.024 |
| Omega 3 (%) | 0.27259 | 0.14209 | 0.063 | 0.132 | 0.17512 | 0.18567 | 0.355 | 0.036 |
| Omega 6 | −0.20296 | 0.51794 | 0.698 | 0.004 | 1.01657 | 0.56466 | 0.084 | 0.135 |
| Alcoholic beverages with | ||||||||
| TNF-α (pgmL) | 0.03047 | 0.15146 | 0.842 | 0.019 | −0.09094 | 0.17645 | 0.611 | 0.012 |
| IL-6 (pgmL) | −0.99832 | 0.98883 | 0.320 | 0.053 | 0.03948 | 0.97002 | 0.968 | 0.024 |
| Hydroxytyrosol (ppm) | −0.02219 | 0.03874 | 0.571 | 0.017 | −0.08268 | 0.02863 | 0.009 | 0.302 |
| Tyrosol (ppm) | 0.00420 | 0.01449 | 0.774 | 0.004 | −0.00624 | 0.00872 | 0.484 | 0.090 |
Models adjusted for group assignment. CRP: C-Reactive Protein; MUFA: Monounsaturated fatty acids; TNF-α: Tumor necrosis factor; IL-6: Interleukin 6; SFA: Saturated Fatty Acids; mMDS: modified Mediterranean Diet Score.
Spearman’s correlations of dietary fatty acid intakes with their corresponding plasma biomarkers at baseline and 6 months follow up in the pilot study of the “Feeding Americas Bravest.”
| Baseline Corresponding Plasma Biomarker | 6-Months Follow up Corresponding Plasma Biomarker | |||||||
|---|---|---|---|---|---|---|---|---|
| Control | Intervention | Control Intervention | Intervention Self-Sustained Phase | |||||
| Nutrients (from FFQ) | ||||||||
| SFA | 0.137 | 0.524 | 0.178 | 0.406 | −0.038 | 0.874 | 0.295 | 0.194 |
| Lauric fatty acid | −0.094 | 0.662 | 0.227 | 0.286 | −0.191 | 0.420 | −0.054 | 0.818 |
| Myristic fatty acid | −0.123 | 0.566 | 0.166 | 0.439 | −0.315 | 0.177 | 0.184 | 0.425 |
| Palmitic fatty acid | −0.096 | 0.654 | 0.133 | 0.537 | 0.177 | 0.455 | 0.570 | 0.007 |
| Stearic fatty acid | 0.020 | 0.925 | −0.072 | 0.738 | 0.387 | 0.092 | −0.128 | 0.581 |
| Palmitoleic acid | −0.039 | 0.857 | 0.018 | 0.935 | −0.614 | 0.004 | 0.226 | 0.324 |
| MUFA | 0.079 | 0.715 | 0.152 | 0.477 | −0.295 | 0.206 | 0.262 | 0.251 |
| Oleic acid | −0.165 | 0.441 | −0.357 | 0.087 | 0.062 | 0.795 | 0.021 | 0.928 |
| PUFA | −0.260 | 0.220 | −0.059 | 0.785 | 0.134 | 0.573 | −0.316 | 0.163 |
| Linoleic acid | −0.191 | 0.373 | 0.210 | 0.324 | 0.127 | 0.593 | −0.090 | 0.699 |
| Alfa-Linolenic acid | 0.217 | 0.307 | 0.302 | 0.152 | 0.073 | 0.760 | −0.083 | 0.722 |
| Omega-3 fatty acids | 0.624 | 0.001 | 0.381 | 0.066 | 0.741 | <0.001 | 0.396 | 0.075 |
| Eicosapentaenoic fatty acid (EPA) | 0.466 | 0.022 | 0.441 | 0.031 | 0.688 | <0.001 | 0.621 | 0.003 |
| Docosahexahenoico (DHA) | 0.673 | <0.001 | 0.347 | 0.097 | 0.775 | <0.001 | 0.292 | 0.198 |
| Total Trans fatty acid | 0.080 | 0.711 | −0.033 | 0.878 | −0.081 | 0.733 | −0.059 | 0.800 |
| Conjugated linoleic acid | −0.148 | 0.490 | 0.122 | 0.570 | −0.066 | 0.783 | 0.726 | <0.001 |
SFA: Saturated Fatty Acids; MUFA: Monounsaturated fatty acids; PUFA: polyunsaturated fatty acids.